🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. AZD1163 Placebo, AZD1163

    AstraZeneca AB

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  2. AZD2014

    United Therapeutics Europe Ltd

    Neurofibromatosis 2

    phase 2 small molecule completed

    1 trial

  3. AZD2014

    Samsung Bioepis NL B.V.

    Cancer of Stomach

    phase 2 small molecule terminated

    1 trial

  4. AZD2281

    AstraZeneca

    Ovarian Neoplasms

    phase 2 small molecule completed

    1 trial

  5. AZD2962, AZD2962

    AstraZeneca AB

    Myelodysplastic syndromes, Dysplastic chronic myelomonocytic leukaemia

    phase 2 small molecule active

    1 trial

  6. AZD3632, AZD3632

    AstraZeneca AB

    Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes with HOX overexpression genotypes

    phase 2 small molecule active

    1 trial

  7. AZD4360

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. AZD4512

    AstraZeneca AB

    Non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  9. AZD4512

    AstraZeneca AB

    B-cell acute lymphoblastic leukemia (B-ALL)

    phase 2 small molecule active

    1 trial

  10. AZD4604, AZD4604 Placebo, AZD4604

    AstraZeneca AB

    Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

    phase 2 small molecule active

    1 trial

  11. AZD4604, Azd4604 placebo, AZD4604

    AstraZeneca AB

    Asthma

    phase 2 small molecule active

    1 trial

  12. AZD5004, AZD5004, AZD5004, Rybelsus 14 mg tablets, Placebo to match AZD5004 (PTM) film-coated tablets, Rybelsus 7 mg tablets, Rybelsus 3 mg tablets

    AstraZeneca AB

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  13. AZD5004, Placebo to match AZD5004 film coated tablet, AZD5004, AZD5004

    AstraZeneca AB

    Participants living with Obesity or Overweight with at least 1 comorbidity

    phase 2 small molecule active

    1 trial

  14. AZD6738, Ceralasertib

    AstraZeneca AB

    Advanced Cancer Whose Tumours Contain Molecular Alterations

    phase 2 small molecule active

    1 trial

  15. AZD6738, Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets, Ceralasertib, AZD6738

    AstraZeneca AB

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  16. AZD7789

    AstraZeneca AB

    Advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma, Advanced or Metastatic Non-small Cell Lung Carcinoma, Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  17. AZD8931

    AstraZeneca

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  18. AZD8931

    United Therapeutics Europe Ltd

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  19. AZD9291

    Hospital Authority, Hong Kong

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  20. AZD9291

    Samsung Bioepis NL B.V.

    Non-Small Cell Lung Cancer With EGFR T790M Mutation

    phase 2 small molecule active

    1 trial

  21. AZD9574, DS-8201a, TEMOZO-cell ®250 mg Hartkapseln, AZD9574, TEMOZO-cell® 140 mg Hartkapseln, TEMOZO-cell® 100 mg Hartkapseln, TEMOZO-cell® 20 mg Hartkapseln, AZD9574, TEMOZO-cell® 180 mg Hartkapseln, TEMOZO-cell® 5 mg Hartkapseln, AZD9574, Datopotamab deruxtecan

    AstraZeneca AB

    Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, Module 4: advanced,unresectable and HER2+ metastatic solid tumours; NSCLC, HER2 activating mutation, Module 5: advanced,unresectable or metastatic solid tumours in breast, endometrial, ovarian and prostate cancer, Module 3: advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, IDH-mutant recurrent glioma, breast cancer (without BM), Module 2: IDH-mutant glioma

    phase 2 small molecule active

    1 trial

  22. AZD9750, Saruparib

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  23. AZD9793

    AstraZeneca AB

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  24. AZITROMICINA ZENTIVA 500 mg compresse rivestite con film, Bassado 100 mg compresse, CEBION

    Sana Biotechnology

    Breast Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources